Pfizer busy in Asia amid patent setback for Sutent in India
This article was originally published in Scrip
Executive Summary
There's a lot happening at Pfizer in Asia or so it seems. The American multinational is fighting hard to defend patents in India and is constantly speculated to be eying an Indian buy, has cut back on clinical research in Singapore, and is maybe bulking up in China. All in all indicative that Asia is perhaps at the nub of activity for Pfizer currently.